Same molecule, three names
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It's the active pharmaceutical ingredient in both Mounjaro and Zepbound. The molecule binds and activates GLP-1 and GIP receptors, slowing gastric emptying, increasing satiety, and improving insulin sensitivity. The clinical effect is the same regardless of which name appears on the box.
What Mounjaro is
Mounjaro is Eli Lilly's tirzepatide product approved by the FDA in 2022 for adults with type 2 diabetes. The labeling, packaging, and insurance coverage are oriented around blood sugar control. Most insurance plans that cover Mounjaro require a documented diabetes diagnosis.
What Zepbound is
Zepbound is the same tirzepatide molecule, approved by the FDA in late 2023 specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27 with weight-related comorbidities). Same molecule. Different label. Different insurance pathway. The clinical mechanism in your body is identical.
Compounded tirzepatide
Compounded tirzepatide is the same active pharmaceutical ingredient prepared by FDA-registered 503A pharmacies under physician prescriptions. Quality is monitored at the pharmacy level, with batch identity and potency testing. The advantages of the compounded route:
- Custom dosing. Brand pens come in fixed strengths. Compounded vials can be filled at any dose your physician prescribes, useful for microdose protocols (see), slow titration, and patients who don't tolerate fixed-step increases.
- Accessibility during shortage. When brand-name supply is constrained (as has happened repeatedly), 503A pharmacies can legally continue to prepare patient-specific compounds.
- Consistent oversight. Reputable U.S. 503A pharmacies, the kind OPTML uses, maintain identity, sterility, and potency standards that put them in a fundamentally different category from gray-market or research-only sources, which we cover in.
The active ingredient, tirzepatide, is the same. The clinical outcomes track accordingly.
How to choose between them
| Pathway | Best fit for |
|---|---|
| Mounjaro (Eli Lilly) | Patients with type 2 diabetes whose insurance covers it |
| Zepbound (Eli Lilly) | Patients with obesity/overweight whose insurance covers it |
| Compounded tirzepatide (U.S. 503A) | Patients wanting custom dosing, slow titration, or who can't access brand routes |
All three deliver the same molecule. The decision is about which pathway fits your situation.
The principle: Tirzepatide is tirzepatide. Mounjaro, Zepbound, and properly compounded versions all activate the same receptors and produce the same clinical effects. Choose the pathway that matches your access and goals.
Bottom line
Mounjaro and Zepbound are two FDA-approved Eli Lilly products containing tirzepatide, same molecule, different indications. Compounded tirzepatide from a reputable U.S. 503A pharmacy contains the same active ingredient with added dosing flexibility. OPTML offers all three pathways with the same physician oversight, lab work, and clinical structure. The right choice depends on your goals, insurance, and whether dosing flexibility matters.